Events
UCPCC Seminar Series
All seminars are held on the first Tuesday of each month from 8:00-9:00 AM PT.
March 7, 2023: David Ting, Harvard University
The Infectious Nature of Pancreatic Cancer Plasticity
Join the meeting using this link
April 4, 2023:
Herve Tiriac, UC San Diego, and Christopher Halbrook, UC Irvine
Defining the metabolic vulnerabilities of chemoresistant pancreatic cancer
Join the meeting using this link
May 2, 2023: Corina Antal, UC San Diego
A super-enhancer regulated RNA-binding protein cascade drives pancreatic cancer
Join the meeting using this link
June 6, 2023: Rosalie Sears, Oregon Health & Sciences University
Title TBD
Join the meeting using this link
Who We Are
The mission of the UC Pancreatic Cancer Consortium (UCPCC) is to unite scientists and clinicians across the UC cancer centers committed to pancreatic cancer research and treatment in a highly collaborative environment that accelerates the progress and impact of our work.
Our vision is to improve the lives of persons diagnosed with pancreatic cancer by translating innovative research into improved clinical care.
UCPCC UC Leaders:
UC Davis Comprehensive Cancer Center – Richard Bold
UCI Chao Family Comprehensive Cancer Center – Murray Korc
UCLA Jonsson Comprehensive Cancer Center – Timothy Donahue
UC San Diego Moores Cancer Center – Andrew Lowy
UCSF Helen Diller Family Comprehensive Cancer Center – Margaret Tempero
Left to right; Dr’s Richard Bold, Andrew Lowy, Margaret Tempero, Tannishtha Reya, Julie Sutcliffe and Katie Couric at the Stand Up To Cancer 2019 Scientific Summit in Santa Monica, CA.
UC Pancreatic Cancer Consortium Working Groups:
-
Biobanking
-
Early Biology
-
Early Detection
-
Imaging
-
Inherited Susceptibility
-
PDAC Clinical Trials
-
Technology Assessment
-
PNET
Funding Opportunities
The UC Pancreatic Cancer Consortium supports pilot projects to encourage collaboration between UC campuses. RFPs will be posted here.
For additional information or guidance, contact Kurt Giles (kurt.giles@ucsf.edu).
Pilot Awards:
-
2023
-
Germline Testing in Pancreatic Neuroendocrine Tumors: Emily Bergsland (UCSF), Joel (Randy) Hecht (UCLA), and Andrew Lowy (UCSD)
-
-
2022
-
Development and Validation of an Artificial Intelligence Platform to Predict Negative-Margin (R0) Resectability of Pancreatic Ductal Adenocarcinoma Based on Preoperative CT Scans: Adnan Alseidi (UCSF) and Timothy Donahue (UCLA)
-
-
2021
-
Defining the metabolic vulnerabilities of chemoresistant pancreatic cancer: Christopher Halbrook (UCI) and Herve Tiriac (UCSD)
-
Copyright 2021 © Regents of the University of California